TECH Bio-Techne
FY2025 10-K
Bio-Techne (TECH) filed its fiscal year 2025 10-K annual report with the SEC on Aug 22, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Life sciences reagents, instruments, and services for research and clinical diagnostics
- • No new products, services, or segments introduced or emphasized this year according to filing text
Management Discussion & Analysis
- • Revenue $1.22B in FY2025, up 5% YoY; Protein Sciences sales $870.2M (+5%), Diagnostics and Spatial Biology $346.3M (+6%)
- • Gross margin declined to 64.8% in FY2025 vs 66.4% in FY2024; Protein Sciences margin 75.6% vs 75.7%, Diagnostics 57.3% vs 58.7%
Risk Factors
- • Cybersecurity risk due to potential breaches despite industry-standard defenses, reliance on third-party software and service providers increasing vulnerability
- • Cyber insurance coverage may be insufficient to cover claims arising from security breaches or cyberattacks
Financial SummaryXBRL
Revenue
$1.2B
Net Income
$73M
Gross Margin
64.8%
Operating Margin
8.4%
Net Margin
6.0%
ROE
3.8%
Total Assets
$2.6B
EPS (Diluted)
$0.46
Operating Cash Flow
$288M
Source: XBRL data from Bio-Techne FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Bio-Techne
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.